Agios Pharmaceuticals Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 AGIOS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) (Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the ExchangeAct).Yes☐No☒ Number of shares of the registrant’s Common Stock, $0.001 par value, outstanding on April24, 2026: 59,471,609 Table of Contents Available Information about Agios Pharmaceuticals, Inc. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to thesereports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free ofcharge on our website located at www.agios.com as soon as reasonably practicable after they are filed with or furnished to theSecurities and Exchange Commission, or SEC. These reports are also available at the SEC’s website at www.sec.gov. We may also disclose information to the public concerning our business, products and product candidates and other items through avariety of disclosure channels in order to achieve broad, non-exclusionary distribution of information to the public, including pressreleases, SEC filings and public conference calls and webcasts. Some of the information distributed through these disclosure channelsmay be considered material information. Investors and others are encouraged to review the information we make public through ourdisclosure channels. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and givenotice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences).Such information, which may be deemed material, will be available on the “Investors” section of the Company’s website under the“Events & Presentations” tab. Investors and others are encouraged to monitor the website and review such information Agios makespublic through the website. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events andpresentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the “Investors” section of theCompany’s website and submitting your email address. The Company’s website, and the contents thereof, are not incorporated by reference into this Quarterly Report on Form 10-Q nordeemed filed with the SEC. Table of Contents AGIOS PHARMACEUTICALS, INC.FORM 10-QFOR THE THREE MONTHS ENDED MARCH 31, 2026TABLE OF CONTENTS PARTI. FINANCIAL INFORMATION Item1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets as of March 31, 2026and December31, 20251Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 20252Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2026 and20253Condensed Consolidated Statements of Stockholders' Equity for the Three Months Ended March 31, 2026 and20254Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20255Notes to Condensed Consolidated Financial Statements6Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item3.Quantitative and Qualitative Disclosures About Market Risk27Item4.Controls and Procedures27PARTII. OTHER INFORMATION28Item1A.Risk Factors28Item5.Other Information57Item6.Exhibits58Signatures59 PART I. FINAN